Details of the Drug Reposition

General Information of This Drug (ID: DMGW1ID)

Drug Name
Sirolimus   DMGW1ID
Synonyms
53123-88-9; Rapamune; Rapamycin (Sirolimus); AY-22989; Rapammune; sirolimusum; WY-090217; RAPA; Antibiotic AY 22989; AY 22989; UNII-W36ZG6FT64; CCRIS 9024; CHEBI:9168; SILA 9268A; W36ZG6FT64; HSDB 7284; C51H79NO13; NSC 226080; DE-109; NCGC00021305-05; DSSTox_CID_3582; DSSTox_RID_77091; DSSTox_GSID_23582; Cypher; Supralimus; Wy 090217; Perceiva; RAP; RPM; Rapamycin from Streptomyces hygroscopicus; SIIA 9268A; LCP-Siro; MS-R001; Rapamune (TN); Rapamycin (TN); Sirolimus (RAPAMUNE); Rapamycin C-7, analog 4; Sirolimus (USAN/INN); Sirolimus [USAN:BAN:INN]; Sirolimus, Rapamune,Rapamycin; Heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy; 23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine; 23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine; 23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29; 3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone; Sirolimus (MTOR inhibitor)
Therapeutic Class
Immunosuppressive Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
13 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
Salivary gland squamous cell carcinoma DISDI0CT N.A. Approved [1]
Mucosal melanoma DISBZ12R N.A. Approved [1]
Lung lymphangioleiomyomatosis DISFL3YB N.A. Approved [1]
Intracranial meningioma DISD09EF N.A. Approved [1]
Brainstem neoplasm DIS5NVUG N.A. Approved [1]
Advanced cancer DISAT1Z9 2A00-2F9Z Approved [1]
Plasma cell myeloma DIS0DFZ0 2A83.1 Approved [1]
Non-small-cell lung cancer DIS5Y6R9 2C25.Y Approved [1]
Prostate cancer DISF190Y 2C82.0 Approved [1]
Graft-versus-host disease DIS0QADF 4B24 Approved [1]
Multiple sclerosis DISB2WZI 8A40 Approved [1]
Organ transplant rejection DISDAKTM NE84 Approved [2]
Lymphangioleiomyomatosis DISR0RNB CB07 Approved [3]
------------------------------------------------------------------------------------
⏷ Show the Full List of 13 Indications(s)
1 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Coronavirus Disease 2019 (COVID-19) DISM7GNX 1D6Y Phase 2 [4]
------------------------------------------------------------------------------------
1 Phase 1/2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Dutch elm disease DISA2WYD 8D64 Phase 1/2 [2]
------------------------------------------------------------------------------------
1 Withdrawn Indication(s)
Indication Name Indication ID ICD-11 Status REF
Pemphigus DISZAZ6M N.A. Withdrawn [5]
------------------------------------------------------------------------------------
3 Discontinued in Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Leukemia DISNAKFL N.A. Discontinued in Phase 3 [6]
Renal cell carcinoma DISQZ2X8 2C90 Discontinued in Phase 3 [7]
Eosinophilic esophagitis DISR8WSB DA24.1 Discontinued in Phase 3 [8]
------------------------------------------------------------------------------------
3 Discontinued in Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Eosinophilic gastroenteritis DISYIW4H N.A. Discontinued in Phase 2 [9]
Squamous cell carcinoma DISQVIFL 2B60-2D01 Discontinued in Phase 2 [10]
Metastatic melanoma DISSL43L 2E2Z Discontinued in Phase 2 [11]
------------------------------------------------------------------------------------
6 Investigative Indication(s)
Indication Name Indication ID ICD-11 Status REF
Pancreatic acinar cell carcinoma DISY1IQQ N.A. Investigative [1]
Castration-resistant prostate carcinoma DISVGAE6 N.A. Investigative [1]
Neuroblastoma DISVZBI4 2D11.2 Investigative [1]
Uveitis DISV0RYS 9A96.Z Investigative [12]
Rheumatoid arthritis DISTSB4J FA20 Investigative [1]
Polycystic kidney disease DISWS3UY GB8Y Investigative [1]
------------------------------------------------------------------------------------
⏷ Show the Full List of 6 Indications(s)

References

1 Sirolimus FDA Label
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6031).
3 FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (ANDA) 201578.
4 ClinicalTrials.gov (NCT04341675) Sirolimus Treatment in Hospitalized Patients With COVID-19 Pneumonia. U.S. National Institutes of Health.
5 ClinicalTrials.gov (NCT02397395) An Efficacy, Safety, Tolerability and Pharmacokinetics Study of 12 Weeks Treatment With Simeprevir and Daclatasvir in Participants With Chronic Hepatitis C Virus Genotype 1b or 4 Infection and Either Severe Renal Impairment or End-stage Renal Disease on Hemodialysis.
6 Tanezumab In Osteoarthritis Of The Hip Or Knee
7 A Clinical Study of Patients With Symptomatic NOH to Assess Sustained Effects of Droxidopa Therapy
8 Minimally Invasive Surgical Therapy for BPH
9 ClinicalTrials.gov (NCT01652014) Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies
10 Cyclosporine, Pravastatin Sodium, Etoposide, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
11 Effects of Perioperative Nesiritide or Milrinone Infusion on Recovery From Fontan Surgery
12 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)